{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:25:57Z","timestamp":1773149157610,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"S13","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1007\/bf02990097","type":"journal-article","created":{"date-parts":[[2008,11,15]],"date-time":"2008-11-15T09:39:24Z","timestamp":1226741964000},"page":"34-38","source":"Crossref","is-referenced-by-count":9,"title":["Indications forHelicobacter pylori eradication therapy and firstline therapy regimen in Japan: recommendation by the Japanese Society forHelicobacter Research"],"prefix":"10.1007","volume":"37","author":[{"given":"Kiichi","family":"Satoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02990097_CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/gut.41.1.8","volume":"41","author":"European Helicobacter pylori Study Group (EHPSG)","year":"1997","unstructured":"EuropeanHelicobacter pylori Study Group (EHPSG). Current European concepts in the management ofHelicobacter pylori infection: the Maastricht consensus report. Gut 1997;41:8\u201313.","journal-title":"Gut"},{"key":"BF02990097_CR2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0016-5085(97)80003-0","volume":"113","author":"DA Peura","year":"1997","unstructured":"Peura DA. The report of the Digestive Health Initiative international update conference onHelicobacter pylori. Gastroenterology 1997;113:S4\u20138.","journal-title":"Gastroenterology"},{"key":"BF02990097_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1746.1998.tb00537.x","volume":"13","author":"SK Lam","year":"1998","unstructured":"Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management ofHelicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1\u201312.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"BF02990097_CR4","first-page":"2","volume":"2","author":"M Asaka","year":"2000","unstructured":"Asaka M, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, et al. Guideline of diagnosis and treatment ofH. pylori infection (in Japanese). Jpn JHelicobacter Res 2000;2(suppl 1):2\u201312.","journal-title":"Jpn J Helicobacter Res"},{"key":"BF02990097_CR5","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1053\/gast.1996.v110.pm8613015","volume":"110","author":"RJ Hopkins","year":"1996","unstructured":"Hopkins RJ, Girardi LS, Turney EA. Relationship betweenHelicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244\u201352.","journal-title":"Gastroenterology"},{"key":"BF02990097_CR6","unstructured":"Kimura K, Asaka M, Toyota T, Satoh K, Kuwayama H, Sakaki N, et al. Phase 2 trial of dual therapy with lansoprazole and amoxicillin forHelicobacter pylori infection: multicenter trial in Japan (in Japanese). In: Abstracts of the 4th annual meeting of Japanese Society forHelicobacter research, June 1998, Sapporo, p. 73 (abstract)."},{"key":"BF02990097_CR7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(97)04523-6","volume":"350","author":"FKL Chan","year":"1997","unstructured":"Chan FKL, Sung JJY, Chung SCS, To KF, Yung MY, Leung VKS, et al. Randomised trial of eradication ofHelicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975\u20139.","journal-title":"Lancet"},{"key":"BF02990097_CR8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(98)04206-8","volume":"352","author":"CJ Hawkey","year":"1997","unstructured":"Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial ofHelicobacter pylori eradication in patients on nonsteroidal anti-inflammatory drugs; HELP NSAIDs study. Lancet 1997;352:1016\u201321.","journal-title":"Lancet"},{"key":"BF02990097_CR9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0140-6736(93)91409-F","volume":"342","author":"AC Wotherspoon","year":"1993","unstructured":"Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication ofHelicobacter pylori. Lancet 1993;342:575\u20137.","journal-title":"Lancet"},{"key":"BF02990097_CR10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/0140-6736(93)91404-A","volume":"342","author":"M Stolte","year":"1993","unstructured":"Stolte M, Edit S. Healing gastric MALT lymphomas by eradicatingHelicobacter pylori. Lancet 1993;342:568.","journal-title":"Lancet"},{"key":"BF02990097_CR11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0140-6736(95)90679-7","volume":"345","author":"C Montalban","year":"1995","unstructured":"Montalban C, Manzanal A, Boixeda D, Redondo C, Bellas C. Treatment of low grade gastric MALT lymphoma withHelicobacter pylori eradication. Lancet 1995;345:798\u20139.","journal-title":"Lancet"},{"key":"BF02990097_CR12","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(95)90113-2","volume":"345","author":"E Bayerd\u00f6effer","year":"1995","unstructured":"Bayerd\u00f6effer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Edit S, et al. Regression of primary gastric lymphoma of mucosaassociated lymphoid tissue type after cure ofHelicobacter pylori infection. Lancet 1995;345:1591\u20134.","journal-title":"Lancet"},{"key":"BF02990097_CR13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00004836-199509000-00011","volume":"21","author":"G Cammarota","year":"1995","unstructured":"Cammarota G, Tursi A, Montalto M, Papa A, Branca G, Vecchio FM, et al. Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-H.pylori therapy. J Clin Gastroenterol 1995;21:118\u201322.","journal-title":"J Clin Gastroenterol"},{"key":"BF02990097_CR14","first-page":"639","volume":"6","author":"N Uemura","year":"1997","unstructured":"Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect ofHelicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6: 639\u201342.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BF02990097_CR15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.7326\/0003-4819-129-9-199811010-00006","volume":"129","author":"T Ohkusa","year":"1998","unstructured":"Ohkusa T, Takashimizu I, Fujiki K, Suzuki S, Shimoi K, Horiuchi T, et al. Disappearance of hyperplastic polyps in the stomach after eradication ofHelicobacter pylori: a randomized, controlled trial. Ann Intern Med 1998;129:712\u20135.","journal-title":"Ann Intern Med"},{"key":"BF02990097_CR16","first-page":"A511","volume":"116","author":"K Sugano","year":"1999","unstructured":"Sugano K, Satoh K, Kihira K, Okamoto S, Sasaki N, Taniyama K, et al. Regression of gastric adenomas by eradication ofHelicobacter pylori. Gastroenterology 1999;116:A511 (abstract).","journal-title":"Gastroenterology"},{"key":"BF02990097_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1523-5378.1997.tb00060.x","volume":"2","author":"B Annibale","year":"1997","unstructured":"Annibale B, Marignani M, Azzoni C, D\u2019Ambra G, Caruana P, D\u2019Adda T, et al. Atrophic body gastritis: distinct features associated withHelicobacter pylori infection. Helicobacter 1997;2: 57\u201364.","journal-title":"Helicobacter"},{"key":"BF02990097_CR18","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/j.1572-0241.1998.00454.x","volume":"93","author":"A Tucci","year":"1998","unstructured":"Tucci A, Poli L, Tosetti C, Biasco G, Grigioni W, Varoli O, et al. Reversal of fundic atrophy after eradication ofHelicobacter pylori. Am J Gastroenterol 1998;93:1425\u201331.","journal-title":"Am J Gastroenterol"},{"key":"BF02990097_CR19","first-page":"A318","volume":"114","author":"RWM Hulst Van der","year":"1998","unstructured":"Van der Hulst RWM, ten Kate FJW, Rauws EAJ, van der Ende A, K\u00f6yc\u00fc B, Tyssen JGP, et al. The relation of CagA and the long-term sequelae of gastritis after successful cure ofH. pylori infection: a long-term follow-up study. Gastroenterology 1998; 114:A318\u201319 (abstract).","journal-title":"Gastroenterology"},{"key":"BF02990097_CR20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/jcp.48.3.250","volume":"48","author":"EM Witteman","year":"1995","unstructured":"Witteman EM, Mravunac M, Becx MJCM, Hopman WPM, Verschoor JSC, Tytgat GNJ, et al. Improvement of gastric inflammation and resolution of epithelial damage one year after eradication ofHelicobacter pylori. J Clin Pathol 1995;48:250\u20136.","journal-title":"J Clin Pathol"},{"key":"BF02990097_CR21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1440-1746.1996.tb00312.x","volume":"11","author":"GM Forbes","year":"1996","unstructured":"Forbes GM, Warren JR, Glaser ME, Cullen DJ, Marshall BJ, Collins BJ. Long-term follow-up of gastric histology afterHelicobacter pylori eradication. J Gastroenterol Hepatol 1996;11: 670\u20133.","journal-title":"J Gastroenterol Hepatol"},{"key":"BF02990097_CR22","doi-asserted-by":"crossref","first-page":"A156","DOI":"10.1016\/S0016-5085(98)80634-3","volume":"114","author":"K Iijima","year":"1998","unstructured":"Iijima K, Ohara S, Sekine H, Koike T, Kubota Y, Kato K, et al. Recovery of gastric acid secretion and mucosal atrophy afterH. pylori eradication in severe atrophie gastritis. Gastroenterology 1998;114:A156\u20137 (abstract).","journal-title":"Gastroenterology"},{"key":"BF02990097_CR23","doi-asserted-by":"crossref","first-page":"A301","DOI":"10.1016\/S0016-5085(99)70126-5","volume":"116","author":"R Sato","year":"1999","unstructured":"Sato R, Fujioka T, Murakami K, Kodama M, Kubota T, Nasu M. Cure ofHelicobacter pylori infection improves gastric atrophy: evaluation by five sites biopsy recommended in the updated Sydney system. Gastroenterology 1999;116:A301 (abstract).","journal-title":"Gastroenterology"},{"key":"BF02990097_CR24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2036.1999.00459.x","volume":"13","author":"K Haruma","year":"1999","unstructured":"Haruma K, Mihara M, Okamoto E, Kusunoki H, Hananoki M, Tanaka S, et al. Eradication ofHelicobacter pylori increases gastric acidity in patients with atrophie gastritis of the corpus: evaluation of 24-h pH monitoring. Aliment Pharmacol Ther 1999;13:155\u201362.","journal-title":"Aliment Pharmacol Ther"},{"key":"BF02990097_CR25","first-page":"236","volume":"3","author":"K Satoh","year":"1998","unstructured":"Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication ofHelicobacter pylori. Helicobacter 1998;3:236\u201340.","journal-title":"Helicobacter"},{"key":"BF02990097_CR26","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJM199812243392601","volume":"339","author":"K McColl","year":"1998","unstructured":"McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al. Symptomatic benefit from eradicatingHelicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869\u201374.","journal-title":"N Engl J Med"},{"key":"BF02990097_CR27","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJM199812243392602","volume":"339","author":"AL Blum","year":"1998","unstructured":"Blum AL, Talley NJ, O\u2019Mor\u00e1in C, van Zanten SV, Labenz J, Stolte M, et al. Lack of effect of treatingHelicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1875\u201381.","journal-title":"N Engl J Med"},{"key":"BF02990097_CR28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.318.7187.833","volume":"318","author":"NJ Talley","year":"1999","unstructured":"Talley NJ, Janssens J, Lauritsen K, R\u00e1cz I, Bolling-Sternevald E. Eradication ofHelicobacter pylori in functional dyspepsia: randomized double blind placebo controlled trial with 12 months\u2019 follow up. BMJ 1999;318:833\u20137.","journal-title":"BMJ"},{"key":"BF02990097_CR29","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM199910073411502","volume":"341","author":"NJ Talley","year":"1999","unstructured":"Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradicatingHelicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106\u201311.","journal-title":"N Engl J Med"},{"key":"BF02990097_CR30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2036.2000.00706.x","volume":"14","author":"H Miwa","year":"2000","unstructured":"Miwa H, Hirai S, Nagahara A, Murai T, Nishira T, Kikuchi S, et al. Cure ofHelicobacter pylori infection does not improve symptoms in nonulcer dyspepsia patients: a double-blind placebocontrolled study. Aliment Pharmacol Ther 2000;14:317\u201324.","journal-title":"Aliment Pharmacol Ther"},{"key":"BF02990097_CR31","doi-asserted-by":"crossref","unstructured":"Asaka M, Sugiyama T, Satoh K, Kuwayama H, Fukuda Y, Fujioka T, et al. Phase 3 double-blind trial ofHelicobacter pylori eradication therapy with lansoprazole, amoxicillin and clarithromycin for patients with peptic ulcer disease (in Japanese). In: Abstracts of the 6th annual meeting of Japanese Society forHelicobacter research, June 2000, Tokyo, p. 90 (abstract).","DOI":"10.1046\/j.1523-5378.2001.00037.x"},{"key":"BF02990097_CR32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1523-5378.1998.08041.x","volume":"3","author":"H Miwa","year":"1998","unstructured":"Miwa H, Ohkusa R, Murai T, Nagahara A, Yamada T, Ogihara T, et al. Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy forHelicobacter pylori infection in a Japanese population. Helicobacter 1998;3:132\u20138.","journal-title":"Helicobacter"},{"key":"BF02990097_CR33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1440-1746.1999.01867.x","volume":"14","author":"H Miwa","year":"1999","unstructured":"Miwa H, Nagahara A, Sato K, Ohkura R, Murai T, Shimizu H, et al. Efficacy of 1 week omeprazole or lansoprazole-amoxycillinclarithromycin therapy forHelicobacter pylori infection in the Japanese population. J Gastroenterol Hepatol 1999;14:317\u201321.","journal-title":"J Gastroenterol Hepatol"},{"key":"BF02990097_CR34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2036.1999.00526.x","volume":"13","author":"H Miwa","year":"1999","unstructured":"Miwa H, Okura R, Murai T, Sato K, Nagahara A, Hirai S, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy forHelicobacter pylori infection. Aliment Pharmacol Ther 1999;13:741\u20136.","journal-title":"Aliment Pharmacol Ther"},{"key":"BF02990097_CR35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1523-5378.1998.08021.x","volume":"3","author":"J Suzuki","year":"1998","unstructured":"Suzuki J, Mine T, Kobayasi I, Fujita T. Assessment of a new triple agent regimen for the eradication ofHelicobacter pylori and the nature ofH. pylori resistance to this therapy in Japan. Helicobacter 1998;3:59\u201363.","journal-title":"Helicobacter"},{"key":"BF02990097_CR36","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2036.1999.00555.x","volume":"13","author":"MHMG Houben","year":"1999","unstructured":"Houben MHMG, van de Beek D, Hensen EF, de Craen AJM, Rauws EAJ, Tytgat GNJ. A systematic review ofHelicobacter pylori eradication therapy: the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047\u201355.","journal-title":"Aliment Pharmacol Ther"},{"key":"BF02990097_CR37","first-page":"423","volume":"2","author":"K Murakami","year":"1998","unstructured":"Murakami K, Fujioka T. Eradication therapy forHelicobacter pylori infection and drug resistance in Japan (in Japanese). Helicobacter Res 1998;2:423\u20138.","journal-title":"Helicobacter Res"},{"key":"BF02990097_CR38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0016-5085(99)70119-8","volume":"116","author":"T Lind","year":"1999","unstructured":"Lind T, M\u00e9graud F, Unge P, Baterd\u00f6rffer E, O\u2019Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication ofHelicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248\u201353.","journal-title":"Gastroenterology"},{"key":"BF02990097_CR39","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2036.1998.00378.x","volume":"12","author":"L Laine","year":"1998","unstructured":"Laine L, Suchower L, Franz J, Connors A, Neil G. Low rate of emergence of clarithromycin-resistantHelicobacter pylori with amoxycillin co-therapy. Aliment Pharmacol Ther 1998;12:887\u201392.","journal-title":"Aliment Pharmacol Ther"},{"key":"BF02990097_CR40","first-page":"10","volume":"35","author":"S Hoshiya","year":"2000","unstructured":"Hoshiya S, Watanabe K, Tokunaga K, Tanaka A, Ninomiya H, Shingaki M, et al. Relationship between eradication therapy and clarithromycin-resistantHelicobacter pylori. J Gastroenterol 2000;35:10\u20134.","journal-title":"J Gastroenterol"},{"key":"BF02990097_CR41","first-page":"137","volume":"95","author":"M Asaka","year":"1998","unstructured":"Asaka M, Fujioka T. Panel discussion: problems after eradication ofHelicobacter pylori (in Japanese). Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol) 1998;95(suppl):137\u201340 (abstract).","journal-title":"Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol)"},{"key":"BF02990097_CR42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-2036.2000.00758.x","volume":"14","author":"H Hamada","year":"2000","unstructured":"Hamada H, Haruma K, Mihara M, Kamada T, Yoshihara M, Sumii K, et al. High incidence of reflux oesophagitis after eradication therapy forHelicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000;14:729\u201335.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02990097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02990097\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02990097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T18:04:43Z","timestamp":1558461883000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02990097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":42,"journal-issue":{"issue":"S13","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["BF02990097"],"URL":"https:\/\/doi.org\/10.1007\/bf02990097","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}